

# CITATION REPORT

List of articles citing

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

DOI: 10.1007/s00262-004-0593-x

Cancer Immunology, Immunotherapy, 2005, 54, 307-14.

**Source:** <https://exaly.com/paper-pdf/38411005/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
478	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. <b>2006</b> , 5, 773-81		9
477	B7-H3 and B7-H4 expression in non-small-cell lung cancer. <b>2006</b> , 53, 143-51		249
476	Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. <b>2006</b> , 47, 4607-13		11
475	Targeting tumor-related immunosuppression for cancer immunotherapy. <b>2006</b> , 6, 233-7		57
474	Immunology: exhausted T cells perk up. <b>2006</b> , 439, 669-70		11
473	Earth science: the rise and growth of Tibet. <b>2006</b> , 439, 670-1		131
472	Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy. <b>2006</b> , 174, 74-81		11
471	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. <b>2006</b> , 119, 317-27		249
470	Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. <b>2006</b> , 12, 4794-803		90
469	Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. <b>2006</b> , 24, 5060-9		257
468	PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. <b>2007</b> , 22, 1527-36		42
467	PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. <b>2007</b> , 13, 1757-61		431
466	Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. <b>2007</b> , 13, 5256-61		181
465	Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. <b>2007</b> , 116, 2062-71		164
464	CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. <b>2007</b> , 178, 6840-8		94
463	The new B7s: playing a pivotal role in tumor immunity. <b>2007</b> , 30, 251-60		157
462	Non-MHC ligands for inhibitory immune receptors: novel insights and implications for immune regulation. <b>2007</b> , 44, 2153-64		28

461	Immunosuppressive strategies that are mediated by tumor cells. <b>2007</b> , 25, 267-96		1260
460	Limited costimulatory molecule expression on renal tubular epithelial cells impairs T cell activation. <b>2007</b> , 30, 421-9		19
459	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. <b>2007</b> , 110, 2614-27		231
458	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. <b>2007</b> , 13, 84-8		1020
457	From T-cell activation signals to signaling control of anti-cancer immunity. <b>2007</b> , 220, 151-68		54
456	Virus-based immunotherapy of cancer: what do we know and where are we going?. <b>2007</b> , 115, 1177-93		4
455	An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells. <b>2007</b> , 247, 95-102		11
454	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 1173-82	7-4	345
453	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. <i>Cancer Immunology, Immunotherapy</i> , <b>2007</b> , 56, 739-45	7-4	332
452	FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. <b>2008</b> , 8, 57		151
451	Dendritic cells in cancer immunotherapy. <b>2008</b> , 99, 363-407		55
450	Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. <b>2008</b> , 26, 5275-83		261
449	Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. <b>2008</b> , 39, 1050-8		149
448	Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. <b>2008</b> , 45, 1470-6		190
447	Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. <b>2008</b> , 270, 337-41		34
446	Principles of Molecular Oncology. <b>2008</b> ,		1
445	Immunotherapy opportunities in ovarian cancer. <b>2008</b> , 8, 243-57		52
444	Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory expression on peripheral blood mononuclear cell-derived T cells and monocytes. <b>2009</b> , 16, 1648-53		32

443	Reviving function in CD4+ T cells adapted to persistent systemic antigen. <b>2009</b> , 183, 4284-91		22
442	B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. <b>2009</b> , 11, 757-66		69
441	Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. <b>2009</b> , 183, 7898-908		55
440	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. <b>2009</b> , 11, 394-402		164
439	Immunotherapy of cancer. <b>2009</b> , 625, 41-54		62
438	Adoptiver Transfer tumorantigenspezifischer T-Zellen in der Onkologie. <b>2009</b> , 2, 11-15		
437	Immunotherapy: from basic research to clinical applications. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1129-36	7.4	1
436	The Germinal centre-derived lymphomas seen through their cellular microenvironment. <b>2009</b> , 145, 468-80		39
435	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. <b>2009</b> , 206, 3015-29		1384
434	Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. <b>2009</b> , 276, 47-52		30
433	Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. <b>2009</b> , 8, 91		26
432	Impaired negative regulation of homeostatically proliferating T cells. <b>2009</b> , 113, 622-5		18
431	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2010</b> , 59, 1173-83	7.4	44
430	The classical Hodgkin lymphoma microenvironment and its role in promoting tumour growth and immune escape. <b>2010</b> , 221, 248-63		193
429	Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). <b>2010</b> , 5, e13940		39
428	Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. <b>2010</b> , 70, 9599-610		96
427	Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. <b>2010</b> , 16, 5481-8		16
426	Anti-tumor immunity and mechanism of immunosuppression mediated by tumor cells: role of tumor-derived soluble factors and cytokines. <b>2010</b> , 29, 421-58		7

425	B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. <b>2010</b> , 184, 5466-5474		27
424	Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. <b>2010</b> , 16, 255-67		25
423	An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. <b>2010</b> , 70, 2707-17		60
422	Cellular immunotherapy of cancer. <b>2010</b> , 651, 319-45		8
421	Immunotherapy of Cancer. <b>2010</b> ,		1
420	Directing dendritic cell immunotherapy towards successful cancer treatment. <b>2010</b> , 2, 37-56		80
419	Immunotherapy of melanoma: an update. <b>2011</b> , 20, 145-63		6
418	Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance. <b>2011</b> , 3, 1235-51		39
417	Molecular alterations in glioblastoma: potential targets for immunotherapy. <b>2011</b> , 98, 187-234		25
416	Tumor immune escape mechanisms that operate during metastasis. <b>2011</b> , 12, 1923-36		17
415	New perspectives in glioma immunotherapy. <b>2011</b> , 17, 2439-67		20
414	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <b>2011</b> , 471, 377-81		467
413	PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. <b>2011</b> , 129, 195-201		59
412	Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 123-31	7.4	13
411	Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 173-86	7.4	33
410	Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2011</b> , 60, 965-74	7.4	49
409	High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. <b>2011</b> , 28, 682-8		455
408	Overall survival and PD-L1 expression in metastasized malignant melanoma. <b>2011</b> , 117, 2192-201		178

407	Therapeutic targeting of B7-H1 in breast cancer. <b>2011</b> , 15, 1211-25	34
406	T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. <b>2011</b> , 17, 5736-47	32
405	VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. <b>2011</b> , 208, 577-92	388
404	Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. <b>2011</b> , 71, 4737-41	29
403	Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. <b>2012</b> , 2012, 741741	53
402	PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. <b>2012</b> , 11, 4305-9	80
401	PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy. <b>2012</b> , 1, 86-88	33
400	. <b>2012</b> ,	
399	Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. <b>2012</b> , 98, 751-755	134
398	Immunotherapy for melanoma. <b>2012</b> , 7, 51-68	
397	The expression, function, and clinical relevance of B7 family members in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 1327-41	7-4 62
396	Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. <b>2012</b> , 43, 132-145	7
395	Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. <b>2012</b> , 5, ra46	313
394	Interferon- $\gamma$ -induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. <b>2012</b> , 217, 385-93	116
393	Costimulatory molecule expression on human uveal melanoma cells: functional analysis of CD40 and B7-H1. <b>2012</b> , 96, 98-106	16
392	Mechanisms of immune evasion by gliomas. <b>2012</b> , 746, 53-76	76
391	Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with colon cancer. <b>2012</b> , 508, 229-32	44
390	PD-1 blockade enhances T-cell migration to tumors by elevating IFN- $\gamma$ -inducible chemokines. <b>2012</b> , 72, 5209-18	288

389	Glioma. <b>2012</b> ,		2
388	Mechanisms of Maternal Immune Tolerance During Pregnancy. <b>2012</b> ,		1
387	PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. <b>2012</b> , 130, 2327-36		27
386	Human Dendritic Cells in Cancer. <b>2012</b> , 121-145		
385	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 1101-11	7-4	33
384	Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. <b>2013</b> , 139, 513-22		139
383	Galectins: Key Players in the Tumor Microenvironment. <b>2013</b> , 537-563		2
382	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <b>2013</b> , 9, 391-397		9
381	Immunotherapy of melanoma. <b>2013</b> , 11, 97-105		39
380	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. <b>2013</b> , 139, 667-76		236
379	Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. <b>2013</b> , 87, 1373-84		66
378	Methylation markers of malignant potential in meningiomas. <b>2013</b> , 119, 899-906		19
377	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. <b>2013</b> , 123, 2604-15		174
376	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. <b>2013</b> , 19, 5636-46		485
375	Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression. <i>Oncology Letters</i> , <b>2013</b> , 5, 1519-1526	2.6	13
374	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. <b>2013</b> , 2, 73-90		23
373	Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant. <b>2014</b> , 9, e92380		8
372	Attenuated <i>Listeria monocytogenes</i> : a powerful and versatile vector for the future of tumor immunotherapy. <b>2014</b> , 4, 51		88

371	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. <b>2014,</b>	3
370	Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model. <b>2014, 15, 1153-62</b>	2
369	Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment. <b>2014, 7, 153-60</b>	39
368	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. <b>2014, 26, 204-14</b>	57
367	Hypericin-based Photodynamic Therapy Induces a Tumor-Specific Immune Response and an Effective DC-based cancer Immunotherapy. <b>2014,</b>	14
366	Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. <b>2014, 20, 1223-34</b>	71
365	The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. <b>2014, 7, 1-17</b>	72
364	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. <b>2014, 92, 195-203</b>	79
363	LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. <b>2014, 74, 3418-28</b>	180
362	Tumour-stroma crosstalk in the development of squamous cell carcinoma. <b>2014, 53, 450-8</b>	31
361	PD-1 regulates extrathymic regulatory T-cell differentiation. <b>2014, 44, 2603-16</b>	68
360	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2014, 63, 545-57</b>	7.4 76
359	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. <b>2014, 146, 15-24</b>	375
358	VISTA Regulates the Development of Protective Antitumor Immunity. <b>2014, 74, 1933-44</b>	267
357	Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. <b>2015, 40, 504-507</b>	7
356	Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2). <b>2015,</b>	
355	Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. <b>2015, 5, 15659</b>	93
354	The microenvironment in chronic lymphocytic leukemia: biology and therapeutic translation. <b>2015, 56-71</b>	



353	Repeated episodes of spontaneous regression/progression of cervical adenocarcinoma after adjuvant chemoradiation therapy: a case report. <b>2015</b> , 9, 114		
352	Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis. <b>2015</b> , 94, e1911		21
351	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. <b>2015</b> , 62, 1317-25		11
350	B Cell Epitope-Based Vaccination Therapy. <i>Antibodies</i> , <b>2015</b> , 4, 225-239	7	8
349	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. <b>2015</b> , 8, 1451-7		24
348	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <b>2015</b> , 89, 181-8		195
347	Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo. <b>2015</b> , 76, 57-64		1
346	The challenge of the microenvironment in mantle cell lymphoma. <b>2015</b> , 84-97		
345	Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. <b>2015</b> , 14, 207		107
344	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. <b>2015</b> , 5, 257-267		
343	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 8110-20	5-4	96
342	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <b>2015</b> , 14, 847-56		1248
341	Hematological Effects, Serum, and Pulmonary Cytokine Profiles in a Melanoma Mouse Model Treated with GK1. <b>2015</b> , 30, 247-54		4
340	PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. <b>2015</b> , 32, 212		67
339	Challenges and future perspectives of T cell immunotherapy in cancer. <b>2015</b> , 166, 117-33		37
338	Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. <b>2015</b> , 10, 910-23		390
337	Second-line therapies in metastatic urothelial carcinoma. <b>2015</b> , 29, 341-59, x		4
336	Immune Therapy in GI Malignancies: A Review. <b>2015</b> , 33, 1745-53		29

335	NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren's syndrome. <b>2015</b> , 126, 1-43	30
334	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. <i>Future Oncology</i> , <b>2015</b> , 11, 2299-306	18
333	Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion. <b>2015</b> , 4, e1008334	30
332	Role of the Tumor Microenvironment in Breast Cancer. <b>2015</b> , 82, 142-52	185
331	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <b>2015</b> , 41, 868-76	280
330	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. <b>2015</b> , 19, 201-11	66
329	The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. <b>2015</b> , 62, 190-197	23
328	Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, which Generates Vaccine for Cancer Therapy. <b>2016</b> , 12, 120-32	58
327	Association of the programmed cell death-1 PD1.5 C>T polymorphism with cervical cancer risk in a Chinese population. <b>2016</b> , 15,	10
326	Treatment of Low-Blast Count AML using Hypomethylating Agents. <b>2017</b> , 9, e2017045	
325	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <b>2016</b> , 35, 34-42	55
324	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. <b>2016</b> , 138, 16686-16695	292
323	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. <b>2016</b> , 1, e000083	45
322	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. <b>2016</b> , 54, 17-24	100
321	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <b>2016</b> , 5, e1165377	38
320	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <b>2016</b> , 11, 593-603	12
319	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. <b>2016</b> , 21, 1027-36	95
318	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <b>2016</b> , 33, 59	20

317	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <b>2016</b> , 4, 845-857		72
316	Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors. <b>2016</b> , 179-193		
315	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <b>2016</b> , 99, 79-87		85
314	The immune system and cancer evasion strategies: therapeutic concepts. <b>2016</b> , 279, 541-62		146
313	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <b>2016</b> ,		1
312	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncology Letters</i> , <b>2016</b> , 12, 944-950	2.6	47
311	Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. <b>2016</b> , 49, 393-401		14
310	miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. <b>2016</b> , 7, 11406		182
309	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <b>2016</b> , 33, 80		27
308	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. <b>2016</b> , 197, 953-61		62
307	Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. <b>2016</b> , 69, 25-34		138
306	Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?. <b>2016</b> , 14, 183-7		30
305	Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation. <b>2016</b> , 87, 46-56		37
304	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <b>2016</b> , 22, 3630-42		246
303	In Epstein-Barr virus-associated gastric carcinoma a high density of CD66b-positive tumor-associated neutrophils is associated with intestinal-type histology and low frequency of lymph node metastasis. <b>2016</b> , 468, 539-48		14
302	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. <b>2016</b> , 8, 593-603		109
301	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 797-804	7.4	13
300	Epigenetics in cancer stem cells. <b>2017</b> , 16, 29		195

299	PD-1 expression by canine T cells and functional effects of PD-1 blockade. <b>2017</b> , 15, 1487-1502	33
298	Emerging role of checkpoint blockade therapy in lymphoma. <b>2017</b> , 8, 81-90	20
297	Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human Knock-In Mice. <b>2017</b> , 16, 861-870	62
296	Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. <b>2017</b> , 7, 43827	42
295	Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. <b>2017</b> , 9, 628-637	7
294	Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 627-636 <sup>7.4</sup>	90
293	Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond. <b>2017</b> , 79, 24-33	4
292	PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. <b>2017</b> , 305, 115-127	15
291	Genome-Edited T Cell Therapies. <b>2017</b> , 3, 124-136	9
290	Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. <b>2017</b> , 64, e26613	33
289	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <b>2017</b> , 9, 493-511	44
288	Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <b>2017</b> , 18, 946-957	133
287	[The role of immunooncology in the treatment of urothelial cancer]. <b>2017</b> , 48, 329-335	
286	Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. <b>2017</b> , 18, 50-55	28
285	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. <b>2017</b> , 147, 500-506	36
284	PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 865-876 <sup>7.4</sup>	94
283	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. <b>2017</b> , 19, 1058-1067	27
282	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 877-890 <sup>7.4</sup>	93

281	Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1 immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. <b>2017</b> , 30, 427-439	105
280	Association of PDCD1 gene markers with susceptibility to thyroid cancer. <b>2017</b> , 40, 481-486	11
279	Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. <b>2017</b> , 13, 1049-1060	47
278	When theory meets experiment: the PD-1 challenge. <b>2017</b> , 23, 308	3
277	Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. <b>2017</b> , 20, 609-615	3
276	Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. <b>2017</b> , 43, 1602-1612	48
275	Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. <b>2017</b> , 125, 908-917	8
274	Identification of a novel population of highly cytotoxic c-Met-expressing CD8 T lymphocytes. <b>2017</b> , 18, 1545-1558	18
273	Variant SNPs at the microRNA complementary site in the B7-H1 3' untranslated region increase the risk of non-small cell lung cancer. <b>2017</b> , 16, 2682-2690	21
272	Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. <b>2017</b> , 9,	99
271	Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. <b>2017</b> , 36, 6143-6153	181
270	Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. <b>2017</b> , 114, E5900-E5909	120
269	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <b>2017</b> , 405, 29-37	51
268	Biomarkers of response to PD-1/PD-L1 inhibition. <b>2017</b> , 116, 116-124	185
267	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. <b>2017</b> , 35, 14-20	45
266	Next generation predictive biomarkers for immune checkpoint inhibition. <b>2017</b> , 36, 179-190	67
265	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.. <b>2017</b> , 1, 1-12	5
264	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. <b>2017</b> , 8, 15894-15911	69

263	Management and Supportive Care of Patients Undergoing Immunotherapy. <b>2017</b> ,	
262	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. <b>2017</b> , 9, 741-750	14
261	Immunotherapy in Gastrointestinal Cancers. <b>2017</b> , 2017, 4346576	45
260	Monoclonal Antibodies. <b>2017</b> , 71-95	3
259	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <b>2017</b> , 8, 3251-3260	17
258	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. <b>2017</b> , 5,	12
257	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <b>2017</b> , 8, 41641-41669	13
256	Current status and future prospects of the strategy of combining CAR-T with PD-1 blockade for antitumor therapy (Review). <b>2018</b> , 17, 2083-2088	9
255	Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. <b>2017</b> , 6, S35-S38	6
254	BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. <b>2018</b> , 104, 265-274	24
253	Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma. <b>2018</b> , 73, 397-406	40
252	Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. <b>2018</b> , 143, 1162-1175	33
251	Monoclonal Antibody LMab-13 Detected Human PD-L1 in Lung Cancers. <b>2018</b> , 37, 110-115	31
250	Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. <b>2018</b> , 21, 925-935	10
249	[Advanced bladder cancer : From chemo- to immunotherapy]. <b>2018</b> , 57, 686-692	
248	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <b>2018</b> , 149, 253-261	17
247	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. <b>2018</b> , 7, e1413519	15
246	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. <b>2018</b> , 26, 420-434	79

245	Aktuelle Systemtherapie des metastasierten Harnblasenkarzinoms. <b>2018</b> , 13, 140-147	
244	PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. <b>2018</b> , 139, 281-291	13
243	CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 T Cells. <b>2018</b> , 78, 115-128	142
242	Immunotherapy and Lung Cancer. <b>2018</b> , 501-511.e3	2
241	Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa. <b>2018</b> , 7, e1388484	14
240	Anti-PD-L1/TGFB2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <b>2018</b> , 36, 93.e1-93.e11	23
239	Construction of the PD-L1 Promoter-Luciferase Reporter Expressing Vector for Small Molecule Inhibitors Screening. <b>2018</b> , 705-712	
238	Chimeric antigen receptor transduced T cells: Tuning up for the next generation. <b>2018</b> , 142, 1738-1747	31
237	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <b>2018</b> , 24, 3583-3616	74
236	Recent Progresses in Phototherapy-Synergized Cancer Immunotherapy. <b>2018</b> , 28, 1804688	169
235	The intracellular signalosome of PD-L1 in cancer cells. <b>2018</b> , 3, 26	108
234	T Cell Senescence and Tumor Immunotherapy. <b>2018</b> , 1-24	
233	CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. <b>2018</b> , 126, 732-738	21
232	Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. <b>2018</b> , 7, 3321	20
231	Aktuelle Systemtherapie des metastasierten Harnblasenkarzinoms. <b>2018</b> , 24, 55-63	
230	Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. <b>2018</b> , 38, 4637-4644	19
229	MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. <b>2018</b> , 48, 801-814	52
228	Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 353	8.4 82

227	Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. <b>2018</b> , 19,	29
226	Proposed Molecular and miRNA Classification of Gastric Cancer. <b>2018</b> , 19,	40
225	Elevation of the TP53 isoform $\Delta 33p53$ in glioblastomas: an alternative to mutant p53 in promoting tumor development. <b>2018</b> , 246, 77-88	17
224	A Three-in-One Immunotherapy Nanoweapon via Cascade-Amplifying Cancer-Immunity Cycle against Tumor Metastasis, Relapse, and Postsurgical Regrowth. <b>2019</b> , 19, 6647-6657	62
223	The $\Delta 33p53$ isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. <b>2019</b> , 10, 631	22
222	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. <b>2019</b> , 9, 11131	15
221	Therapeutic outcomes in non-small cell lung cancer with mutations: a single institution, retrospective cohort study. <b>2019</b> , 8, 258-267	7
220	A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model. <b>2019</b> , 14, 222-232	6
219	[50 years of systemic therapy of urinary bladder cancer]. <b>2019</b> , 50, 358-365	2
218	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy. <b>2019</b> , 138, 58-64	2
217	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <b>2019</b> , 145, 3021-3036	11
216	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. <b>2019</b> , 10, 962	16
215	An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. <b>2019</b> , 15, 166-177	7
214	Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. <b>2019</b> , 8, 6114-6126	48
213	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). <b>2019</b> , 7, 20	50
212	Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer. <b>2019</b> , 15, 605-612	1
211	Recent advances in the clinical development of immune checkpoint blockade therapy. <b>2019</b> , 42, 609-626	38
210	Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. <b>2019</b> , 460, 42-53	37



209	Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. <b>2019</b> , 201, 181-201	36
208	Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. <b>2019</b> , 7, 1135-1147	24
207	From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era. <b>2019</b> , 155-172	
206	Gastric Cancer In The Precision Medicine Era. <b>2019</b> ,	
205	Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis. <b>2019</b> , 98, e14006	16
204	PD-L1 Expression Is Associated With VEGFA and LADC Patients'Survival. <b>2019</b> , 9, 189	9
203	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. <b>2019</b> , 10, 475	6
202	Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. <b>2019</b> , 120, 547-554	17
201	Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer. <b>2019</b> , 4, 29	14
200	Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway. <b>2019</b> , 3, 3038-3051	5
199	Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class 1 in non-small cell lung cancer. <b>2019</b> , 42, 839-848	4
198	The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers. <b>2019</b> , 46, 3-10	8
197	Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. <b>2019</b> , 26, 876-883	44
196	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. <b>2019</b> , 293, 104-112	35
195	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <b>2019</b> , 42, 281-294	45
194	Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. <b>2019</b> , 16, 1200-1210	19
193	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <b>2019</b> , 40, 17-65	209
192	Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. <b>2019</b> , 35, 251-256	17

191	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. <b>2019</b> , 335-344		1
190	DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer. <b>2019</b> , 374, 304-314		14
189	The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. <b>2020</b> , 15, 11-19		12
188	Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer. <b>2020</b> , 18, 324-339		19
187	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. <i>Future Oncology</i> , <b>2020</b> , 16, 4439-4453	3.6	21
186	A combination of check-point blockade and galactosylceramide elicits long-lasting suppressive effects on murine hepatoma cell growth in vivo. <b>2020</b> , 225, 151860		1
185	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <b>2020</b> , 10,		4
184	A defucosylated anti-PD-L1 monoclonal antibody 13-mG-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. <b>2020</b> , 24, 100801		2
183	Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker. <b>2020</b> , 11, 3223-3233		0
182	Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. <i>Cancers</i> , <b>2020</b> , 12,	6.6	21
181	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. <b>2020</b> , 8,		10
180	Anti-Tumorigenic Activities of IL-33: A Mechanistic Insight. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 571593	8.4	6
179	Biomaterial-based approaches to engineering immune tolerance. <b>2020</b> , 8, 7014-7032		4
178	PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification. <b>2021</b> , 27, 1699-1710		2
177	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <b>2020</b> , 13, 105		17
176	Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. <b>2020</b> , 9, 231-243		2
175	Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. <b>2020</b> , 8, 1187		10
174	Is DNA Methylation a Ray of Sunshine in Predicting Meningioma Prognosis?. <b>2020</b> , 10, 1323		4

173	Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient. <b>2020</b> , 21,		2
172	Ethyl Acetate Fraction from plus Exerts Anti-Breast Cancer Effect via miR-200c-PDE7B/PD-L1-AKT/MAPK Axis. <b>2020</b> , 2020, 3587095		5
171	A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies. <b>2020</b> , 12, 6493-6509		6
170	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. <b>2020</b> , 8,		18
169	Immunotherapy for advanced or metastatic urothelial carcinoma. <b>2020</b> ,		
168	The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. <b>2020</b> , 26, 5549-5556		30
167	Atezolizumab in the treatment of metastatic triple-negative breast cancer. <b>2020</b> , 20, 981-989		9
166	The cancer-natural killer cell immunity cycle. <b>2020</b> , 20, 437-454		118
165	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. <b>2020</b> , 10, 9705		22
164	Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. <b>2020</b> , 34, 897-914		3
163	Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. <b>2020</b> , 10, 3652		26
162	Cancer Stem Cell Target Labeling and Efficient Growth Inhibition of CD133 and PD-L1 Monoclonal Antibodies Double Conjugated with Luminescent Rare-Earth Tb <sup>3+</sup> Nanorods. <b>2020</b> , 10, 1710		3
161	Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes. <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 1253-1263	7.4	9
160	Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients. <b>2020</b> , 11, 1139-1148		2
159	Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy. <b>2020</b> , 12, 697-703		1
158	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. <b>2020</b> , 17, 807-821		232
157	The Role of PD-1 in Acute and Chronic Infection. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 487	8.4	69
156	The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1435-1450	7.4	11

155	Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. <b>2021</b> , 21, 315-323		4
154	PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases. <b>2021</b> , 41, 133-149		1
153	Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma. <b>2021</b> , 129, 468-478		3
152	Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System. <b>2021</b> , 2279, 35-47		1
151	GRAS-microparticle microarrays identify dendritic cell tolerogenic marker-inducing formulations. <b>2021</b> , 21, 3598-3613		
150	Cytogenetic and Molecular Genetic Abnormalities of CIITA Gene in Patients with Primary Mediastinal (Thymic) Large B-Cell Lymphoma. <b>2021</b> , 14, 173-178		1
149	YY1 expression and PD-1 regulation in CD8 T lymphocytes. <b>2021</b> , 289-309		1
148	Colon cancer and immunotherapy-can we go beyond microsatellite instability?. <b>2021</b> , 6, 12		10
147	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	14
146	Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors. <b>2021</b> , 13, 17588359211020528		0
145	Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment. <b>2021</b> , 22,		16
144	Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions. <b>2021</b> , 13, 113-123		0
143	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <b>2021</b> , 18, 345-362		148
142	Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. <b>2021</b> , 10, 699-711		2
141	Exosomes and cancer: from molecular mechanisms to clinical applications. <b>2021</b> , 38, 45		15
140	Determining mutational burden and signature using RNA-seq from tumor-only samples. <b>2021</b> , 14, 65		1
139	Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. <b>2021</b> , 33, e12943		0
138	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3

137	Gene expression patterns associated with tumor-infiltrating CD4+ and CD8+ T cells in invasive breast carcinomas. <b>2021</b> , 82, 279-287			1
136	Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. <b>2021</b> , 897, 173960			1
135	Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF- $\kappa$ B/STAT3 and NF- $\kappa$ B/CSN5 signaling pathways. <b>2021</b> , 21, 630-641			4
134	Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer. <b>2021</b> , 9, 838-852			2
133	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. <b>2021</b> , 13,			3
132	PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma. <b>2021</b> , 28, 2745-2764			9
131	Avances y perspectivas actuales en recursos y estrategias terapéuticas: fármacos biológicos. <b>2021</b> , 13, 1882-1892			
130	Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. <b>2021</b> , 11, 696716			2
129	Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. <i>Cancers</i> , <b>2021</b> , 13,	6.6		4
128	Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. <i>Future Oncology</i> , <b>2021</b> , 17, 2243-2256	3.6		10
127	Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. <b>2021</b> , 22,			3
126	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <b>2021</b> , 11, 641428			8
125	Innovations in radiotherapy and advances in immunotherapy for the treatment of brain metastases. <i>Clinical and Experimental Metastasis</i> , <b>2021</b> , 1	4.7		3
124	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. <b>2021</b> , 21, 1575-1590			2
123	The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (Review). <b>2021</b> , 46,			1
122	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8		6
121	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <b>2021</b> , 9, 49			6
120	Prospects and Challenges for T Cell-Based Therapies of HCC. <b>2021</b> , 10,			2

119	Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer. <b>2021</b> , 11,		2
118	Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. <b>2021</b> , 21, 927-939		1
117	Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8 T Cells. <b>2021</b> , 9, 1214-1228		2
116	Emerging role of natural products in cancer immunotherapy.. <b>2022</b> , 12, 1163-1185		3
115	Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. <b>2021</b> ,		4
114	Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
113	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. <b>2021</b> ,		1
112	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
111	Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
110	Human V $\beta$ V $\delta$ T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. <b>2021</b> , 573, 132-139		2
109	Therapy of lung cancer in China: introducing the special collection. <b>2021</b> , 13, 17588359211038199		0
108	B7-H abnormalities in melanoma and clinical relevance. <b>2014</b> , 1102, 367-80		2
107	Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. <b>2020</b> , 15, 327-336		7
106	Combining an alarmin HMGN1 peptide with PD-L1 blockade facilitates stem-like CD8+ T cell expansion and results in robust antitumor effects.		1
105	Characterization of human $\gamma\delta$ lymphocytes infiltrating primary malignant melanomas. <b>2012</b> , 7, e49878		92
104	Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer. <b>2016</b> , 7, 59087-59097		50
103	Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. <b>2016</b> , 7, 83817-83827		5
102	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. <b>2017</b> , 8, 30175-30189		53

101	The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. <b>2017</b> , 8, 27189-27198	5
100	Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors. <b>2017</b> , 8, 72755-72772	34
99	Immunotherapy as a targeted therapy in non-small cell lung cancer.. <b>2019</b> , 8, S70-S75	2
98	Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial.. <b>2019</b> , 8, S145-S148	1
97	B7 molecule mRNA expression in colorectal carcinoma. <b>2005</b> , 11, 5655-8	10
96	Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. <b>2014</b> , 26, 104-11	80
95	Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. <b>2015</b> , 7, 462-70	88
94	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist. <b>2020</b> , 4, 837-850	7
93	PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. <b>2012</b> , S12,	21
92	Expression of ICOSL is associated with decreased survival in invasive breast cancer. <b>2019</b> , 7, e6903	9
91	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <b>2021</b> , 1876, 188636	3
90	Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All@ Well That Ends Well?. <b>2008</b> , 293-306	
89	Functional Cytotoxicity of T Cells in the Tumor Microenvironment. <b>2008</b> , 157-170	
88	Immunology of Cancer. <b>2008</b> , 1947-1963	
87	Revisiting the paradigm on the putative need for antigen-specific responses in cancer. <b>2011</b> , 9-24	
86	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. <b>2012</b> , 291-306	
85	Hodgkin lymphoma microenvironment: old and new therapeutic targets. <b>2015</b> , 36-55	
84	Hodgkin lymphoma and its cellular microenvironment. <b>2015</b> , 2-19	

83	The microenvironment in T-cell lymphomas. <b>2015</b> , 112-131		
82	Microenvironment in diffuse large B cell lymphomas. <b>2015</b> , 98-111		
81	Microenvironment in in situ follicular lymphoma and in other early lymphoid lesions. <b>2015</b> , 72-82		
80	Microenvironment-related biomarkers and novel targets in Hodgkin lymphoma. <b>2015</b> , 20-34		
79	Microenvironment in HIV-related lymphomas. <b>2015</b> , 132-150		
78	Targeted Therapies for Hepatocellular Carcinoma. <b>2016</b> , 513-529		
77	Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer. <i>Precision and Future Medicine</i> , <b>2017</b> , 1, 152-158	1.1	
76	T Cell Senescence and Tumor Immunotherapy. <b>2019</b> , 2091-2114		
75	Immunohistochemical Expression of PDL1 in Pre-Malignant and Malignant Lesions of Cervix. <i>Journal of Evidence Based Medicine and Healthcare</i> , <b>2020</b> , 7, 1245-1249	0	
74	A Novel Model Based on Genomic Instability-Associated Long Non-Coding RNAs for Predicting Prognosis and Response to Immunotherapy in Patients With Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 720013	4.5	0
73	Highlights of Immunomodulation in -Based Cancer Therapy. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	0
72	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , <b>2021</b> , 101, 108322	5.8	5
71	Drug Targets for Biologics. <b>2020</b> , 71-88		
70	Neurological Toxicities of Immunotherapy. <b>2020</b> , 223-242		
69	CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer. <i>Cancer Science</i> , <b>2021</b> ,	6.9	2
68	On the Mechanism of T cell receptor down-modulation and its physiological significance. <b>2011</b> , 1,		8
67	Immunity, cancer and aging: lessons from mouse models. <b>2011</b> , 2, 512-23		16
66	Programmed death-1 gene polymorphism (PD-1.5 C/T) is associated with gastric cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , <b>2013</b> , 6, 178-82	1.2	28



65	Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 8086-93		25
64	Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 14595-603		56
63	Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. <i>Oncology Letters</i> , <b>2019</b> , 18, 2661-2669	2.6	2
62	Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
61	A Bispecific Antibody Targeting HER2 and PD-L1 Inhibits Tumor Growth with Superior Efficacy. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 101420	5.4	4
60	Targeting the undruggable oncogenic KRAS: the dawn of hope.. <i>JCI Insight</i> , <b>2022</b> , 7,	9.9	2
59	Urogenital Microbiota:Potentially Important Determinant of PD-L1 Expression in Male Patients with Non-muscle Invasive Bladder Cancer.. <i>BMC Microbiology</i> , <b>2022</b> , 22, 7	4.5	0
58	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials.. <i>Expert Opinion on Investigational Drugs</i> , <b>2022</b> ,	5.9	0
57	Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential.. <i>World Journal of Clinical Cases</i> , <b>2022</b> , 10, 23-34	1.6	
56	The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer.. <i>Cancer Cell International</i> , <b>2022</b> , 22, 3	6.4	
55	Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
54	Perspectives on the role of breast cancer susceptibility gene in breast cancer.. <i>International Journal of Clinical Oncology</i> , <b>2022</b> , 27, 495	4.2	
53	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. <i>Molecular Diagnosis and Therapy</i> , <b>2022</b> , 1	4.5	
52	Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.. <i>Antibodies</i> , <b>2022</b> , 11,	7	0
51	Comparison of Immune Checkpoint Molecules and in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence.. <i>Brain Sciences</i> , <b>2022</b> , 12,	3.4	
50	Cohesin mutation sensitizes cancer cells to anti-PD-1 therapy through endogenous retrovirus-mediated PD-L1 upregulation.		
49	Current Clinical Trial Landscape of OX40 Agonists.. <i>Current Oncology Reports</i> , <b>2022</b> ,	6.3	2
48	LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1.. <i>Bioengineered</i> , <b>2022</b> , 13, 7635-7647	5.7	2

47	Generalizability of ORIENT-11 trial results to a US standard of care cohort with advanced non-small-cell lung cancer.. <i>Future Oncology</i> , <b>2022</b> ,	3.6	0
46	The Role of NcRNAs to Regulate Immune Checkpoints in Cancer.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 853480	4.0	1
45	Vascular Microenvironment, Tumor Immunity and Immunotherapy.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 811485	8.4	6
44	Immunotherapy Resistance in Glioblastoma.. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 750675	4.5	1
43	Data_Sheet_1.pdf. <b>2019</b> ,		
42	Image_1.JPEG. <b>2019</b> ,		
41	Image_2.JPEG. <b>2019</b> ,		
40	Table_1.DOC. <b>2019</b> ,		
39	MHC I Expression Predicts Response to Checkpoint Inhibitors in Metastatic Urothelial Carcinoma but Lacks Prognostic Value in Localized Disease. <i>Bladder Cancer</i> , <b>2022</b> , 1, 1-8	1	0
38	Radiation Therapy for Extracranial Oligometastatic Disease. <b>2022</b> , 681-695		
37	Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR ). <i>Journal of Medical Imaging and Radiation Oncology</i> ,	1.7	1
36	Research Progress of Chemokine and Costimulatory Molecules in the Pathogenesis of Mycoplasma pneumoniae Pneumonia in Children. <i>Advances in Clinical Medicine</i> , <b>2022</b> , 12, 5937-5945	0	
35	Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. <i>Clinical and Experimental Metastasis</i> ,	4.7	3
34	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. 13,		4
33	A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT. 13,		
32	Novel approaches for treatment of endometrial carcinoma. <b>2022</b> , 46, 100895		1
31	A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. <b>2022</b> , 111, 109022		
30	Methionine enkephalin inhibits colorectal cancer by remodeling the immune status of the tumor microenvironment. <b>2022</b> , 111, 109125		0

29	Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. <b>2022</b> , 238, 154110	0
28	Successes and failures of immunotherapy for gastric cancer. <b>2022</b> , 27, 103343	0
27	Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo. <b>2022</b> , 4,	0
26	Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. <b>2022</b> , 11, 2793	0
25	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. <b>2022</b> , 10, 2405	0
24	Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells..	0
23	Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance.	0
22	PD-1 engineered cytomembrane cloaked molybdenum nitride for synergistic photothermal and enhanced immunotherapy of breast cancer.	0
21	AKT Isoforms in the Immune Response in Cancer. <b>2022</b> , 349-366	0
20	Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors. 13,	0
19	Tumor immunomodulatory effects of polyphenols. 13,	0
18	Immune Checkpoint Inhibitor Therapy in Oncology. <b>2022</b> , 4, 579-597	2
17	Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy. <b>2022</b> , 20,	1
16	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms.	0
15	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. <b>2022</b> , 8,	0
14	Perspective Chapter: Impact of Tumor Metabolism on Immune Cells in the Tumor Microenvironment.	0
13	Nanomaterials-involved strategies for reversing the immunosuppressive factors and improving antitumor immunotherapy. <b>2023</b> , 50, 101831	0
12	The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. <b>2023</b> , 162, 114646	0

- 11 Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo. **2023**, 18, ○
- 10 Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis. **2023**, 15, 293-309 ○
- 9 *Salmonella typhimurium* may support cancer treatment: a review. **2023**, ○
- 8 Regulation of programmed death ligand 1 expression by interferon- $\gamma$  and tumour necrosis factor- $\alpha$  in canine tumour cell lines. ○
- 7 PD-1+CD8+ T Cells Proximal to PD-L1+CD68+ Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients. **2023**, 15, 1389 ○
- 6 DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy. **2023**, 15, 1619 ○
- 5 Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. 29, 1470-1482 ○
- 4 Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. 29, 1614-1626 ○
- 3 Anlotinib combined with Sintilimab is win-win cooperation for primary squamous cell carcinoma of the thyroid: A case report and literature review. 13, ○
- 2 Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. **2023**, 12, 472 ○
- 1 Peripheral immune characteristics of hepatitis B virus-related hepatocellular carcinoma. 14, ○